Intended for healthcare professionals

  1. Research
  2. Risk of myocardial...
  3. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
Primary Care

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7504.1366 (Published 09 June 2005) Cite this as: BMJ 2005;330:1366

Related articles

See more

Cited by...

  • Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis
  • Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care
  • Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care
  • Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice
  • Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database
  • Enhanced NF-{kappa}B Activity Impairs Vascular Function Through PARP-1-, SP-1-, and COX-2-Dependent Mechanisms in Type 2 Diabetes
  • High dose NSAIDs may double the risk of heart attacks and heart failure, says new study
  • The Role of Nonsteroidal Antiinflammatory Drugs and Cyclooxygenase-2 Inhibitors on Experimental Colitis
  • Risk of ST versus non-ST elevation myocardial infarction associated with non-steroidal anti-inflammatory drugs
  • Use of Nonsteroidal Antiinflammatory Drugs: Is There a Change in Patient Risk Profile After Withdrawal of Rofecoxib?
  • Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis
  • Metabolic profiling of murine plasma reveals an unexpected biomarker in rofecoxib-mediated cardiovascular events
  • Cause-Specific Cardiovascular Risk Associated With Nonsteroidal Antiinflammatory Drugs Among Healthy Individuals
  • Recent advances in rheumatoid arthritis
  • Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes
  • Using NSAIDs in cardiovascular disease
  • Is the conflict of interest unacceptable when drug companies conduct trials on their own drugs? Yes
  • Disruption of Cholesterol Efflux by Coxib Medications and Inflammatory Processes: Link to Increased Cardiovascular Risk
  • Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients
  • Cyclooxygenase 2-Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs Induce Oxidative Stress by Up-Regulating Vascular NADPH Oxidases
  • N-Terminal Pro-B-Type Natriuretic Peptide Concentrations Predict the Risk of Cardiovascular Adverse Events from Antiinflammatory Drugs: A Pilot Trial
  • Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials
  • Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study
  • An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs
  • Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors
  • Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
  • Culture-Independent Analysis of Indomethacin-Induced Alterations in the Rat Gastrointestinal Microbiota
  • Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction
  • Life without COX 2 inhibitors: Risks and benefits are determined by dose and potency
  • Use of First- and Second-Generation Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction
  • COX-2 inhibitors and the heart: are all coxibs the same?
  • Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events
  • Update on Cyclooxygenase-2 Inhibitors
  • Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
  • Is progressive osteoarthritis an atheromatous vascular disease?
  • COX-2 chronology
  • Do NSAIDs Increase Risk for MI?
  • Cyclooxygenase Inhibition and Cardiovascular Risk
  • Do NSAIDs Increase Risk for MI?
  • Do NSAIDs Increase Risk for MI?
Back to top